Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
Caribou Biosciences, a biotech firm co-founded by Nobel laureate Jennifer Doudna, is halting its pipeline and reducing staff amid potential closure.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Caribou Biosciences halted its CAR-T cancer programs and cut staff amid a challenging funding climate and freezing financing. The company's stock crashed following the decisions, leading to considerations of a fire sale or closure.
The coverage quieted without a definitive conclusion regarding the final outcome of the shutdown process.
Epilogue added 38d ago, after coverage quieted.
The brief
Caribou Biosciences, a biotechnology company co-founded by Nobel laureate Jennifer Doudna, is currently in the process of shutting down its operations. According to reports from STAT and Fierce Biotech, the company has made the difficult decision to shrink its overall headcount and halt its existing development pipeline. The firm is specifically stopping the development of two cancer cell therapy programs. These measures indicate a severe contraction of the company's operational capacity as it moves toward a total cessation of its current biotech initiatives. Coverage from various industry outlets emphasizes the severity of these cuts.
FirstWord Pharma reports that the company is canning its CAR-T programs and cutting staff. The Business Journals highlights that this is the first company established by Jennifer Doudna and notes that the organization is now pondering either a complete closure or a fire sale of its assets. Fierce Biotech characterizes the decision to reduce the workforce and stop the pipeline as a heartbreaking call for the organization, reflecting the emotional and professional stakes involved in the dissolution of the firm. To understand why this development is significant, it is necessary to recognize the pedigree of the company's leadership. As co-founded by Jennifer Doudna, a Nobel laureate, Caribou Biosciences represented a major venture in the application of gene-editing technology to medicine.
The focus on CAR-T cell therapies for cancer treatment placed the company at the forefront of high-stakes biotech research. The sudden move to halt these programs and consider a fire sale suggests a critical shift in the company's viability or strategic direction within the competitive cancer therapy landscape. Moving forward, observers will be watching to see if Caribou Biosciences completes a full shutdown or if it successfully executes a fire sale of its remaining assets. Based on the reporting from The Business Journals, the outcome remains uncertain as the company weighs these two options. Additionally, the specific impact on the workforce and the final status of the two halted cancer cell therapy programs will be key indicators of how the company winds down its research activities and handles its intellectual property.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 40d ago.
Quick answers
Who co-founded Caribou Biosciences?
The company was co-founded by Nobel laureate Jennifer Doudna.
What specific programs is the company stopping?
Caribou is halting the development of two cancer cell therapy programs, specifically its CAR-T programs.
What are the potential outcomes for the company's future?
According to The Business Journals, the company is pondering either a full closure or a fire sale.
Coverage (9)
- Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate BioPharma Dive · 41d ago
- A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs www.inc.com · 41d ago
- Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up BioSpace · 41d ago
- CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs Yahoo Finance · 41d ago
- Caribou cans CAR-Ts, cuts staff FirstWord Pharma · 41d ago
- Nobel laureate Jennifer Doudna's first company ponders fire sale, closure The Business Journals · 41d ago
- Two cancer cell therapy programs are set to stop development as Caribou plans job cuts Stock Titan · 41d ago
- CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline Fierce Biotech · 41d ago
- Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down STAT · 41d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.